Zymeworks Inc (ZYME)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

540-1385 WEST 8TH AVENUE VANCOUVER, BRITISH COLUMBIA, CANADA V6H 3V9

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

Data as of 2021-07-19 09:40:27 -0400
Market Cap1.65 Billion Shares Outstanding46.17 Million Avg 30-day Volume437.344 Thousand
P/E Ratio-8.50311 Dividend Yield EPS-3.8
Price/Sales52.66 Debt to Equity1.3 EBITDA-188.143 Million
Price to Book Value4.37 Forward PE Enterprise Value1.238 Billion
Total Cash411.474 Million Current Debt70.245 Million Gross Profit31.326 Million
BETA0.95957 52-week High/Low59.03 / 24.82 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -35.9114
Data provided by IEX Cloud
View SEC Filings from ZYME instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 2 -100.0% 0 (0.0%) 2 (0.12%) -100.0%
Funds Holding: 122 140 -12.86% 45 (2.64%) 47 (2.73%) -4.26%
13F shares: 35.118 Million 34.777 Million 0.98% 19.962 Million 19.317 Million 3.34%
% Ownership 76.0712 75.691 0.5% 43.2409 42.0427 2.85%
New Positions: 19 34 -44.12% 10 14 -28.57%
Increased Positions 56 34 64.71% 18 9 100.0%
Closed Positions 35 22 59.09% 12 11 9.09%
Reduced Positions 30 49 -38.78% 12 21 -42.86%
Total Calls 167.617 Thousand 1.019 Million -83.55% 26 Thousand 626.59 Thousand -95.85%
Total Puts 137.308 Thousand 1.261 Million -89.11% 33.7 Thousand 648.355 Thousand -94.8%
PUT/CALL Ratio 0.82 1.24 -33.87% 1.3 1.03 26.21%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ZYME (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ZYME BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

57.7 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

57.7 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TEHRANI ALI CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
617,352 2021-07-15 5

KLOMPAS NEIL A CHIEF FINANCIAL OFFICER

  • Officer
11,470 2021-07-06 6

POLVERINO ANTHONY J. CHIEF SCIENTIFIC OFFICER

  • Officer
31,433 2021-07-06 3

O'DRISCOLL KATHRYN CHIEF PEOPLE OFFICER

  • Officer
6,350 2021-07-06 5

PRIOUR JAMES CHIEF COMMERCIAL OFFICER

  • Officer
2,513 2021-07-06 4

JOSEPHSON NEIL INTERIM CHIEF MEDICAL OFFICER

  • Officer
2,054 2021-07-06 2

RENTON HOLLINGS

  • Director
9,000 2021-05-06 1

ZOTH LOTA S.

  • Director
9,000 2021-05-06 1

SACKS NATALIE

  • Director
9,000 2021-05-06 1

HILLAN KENNETH J.

  • Director
9,000 2021-05-06 1

MAHONY SUSAN

  • Director
9,000 2021-05-06 1

COX TROY

  • Director
9,000 2021-05-06 1

NEU KELVIN

  • Director
9,000 2021-05-06 1

HAUSMAN DIANA CHIEF MEDICAL OFFICER

  • Officer
69,252 2021-03-10 5

BAKER BROS. ADVISORS LP

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
0 2020-05-08 0

POON DAVID KAI YUEN SEE REMARKS

  • Officer
0 2019-05-06 0

BEDFORD NICK

  • Director
0 2019-05-06 0

LILLY ELI & CO

  • 10% Owner
2,898,647 2019-01-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-16 S 41,191 $36.00 d 260,325 direct yes 1.9119 1.9119 2 0.0 1

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-16 M 41,191 d 0 direct yes

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-16 M 41,191 $4.26 a 301,516 direct yes 1.9119 1.9119 2 0.0 1

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-15 M 3,800 $4.27 a 264,125 direct yes 1.9119 1.9119 2 0.0 1

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-15 M 3,800 d 41,191 direct yes

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-16 21:30:18 -0400 2021-07-15 S 3,800 $36.00 d 260,325 direct yes 1.9119 1.9119 2 0.0 1

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-13 20:00:23 -0400 2021-07-12 M 12,669 $4.31 a 272,994 direct yes 2.3577 6.268 6.268 6 0.0 1

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-13 20:00:23 -0400 2021-07-12 M 12,669 d 44,991 direct yes

TEHRANI ALI - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-13 20:00:23 -0400 2021-07-12 S 12,669 $36.12 d 260,325 direct yes 2.3577 6.268 6.268 6 0.0 1

POLVERINO ANTHONY J. - Officer CHIEF SCIENTIFIC OFFICER

2021-07-08 20:00:37 -0400 2021-07-06 A 454 $29.49 a 31,433 direct -2.8223 -3.0393 0.0 1 -5.7802 3

PRIOUR JAMES - Officer CHIEF COMMERCIAL OFFICER

2021-07-08 20:00:21 -0400 2021-07-06 A 510 $29.49 a 2,513 direct -2.8223 -3.0393 0.0 1 -5.7802 3

O'DRISCOLL KATHRYN - Officer CHIEF PEOPLE OFFICER

2021-07-08 20:05:15 -0400 2021-07-06 A 510 $29.49 a 6,350 direct -2.8223 -3.0393 0.0 1 -5.7802 3

KLOMPAS NEIL A - Officer CHIEF FINANCIAL OFFICER

2021-07-08 20:00:29 -0400 2021-07-06 A 299 $29.49 a 10,770 direct -2.8223 -3.0393 0.0 1 -5.7802 3

JOSEPHSON NEIL - Officer INTERIM CHIEF MEDICAL OFFICER

2021-07-08 20:00:14 -0400 2021-07-06 A 461 $29.49 a 2,054 direct -2.8223 -3.0393 0.0 1 -5.7802 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ZYMEWORKS INC ZYME 2021-07-23 22:15:03 UTC -0.2539 0.3339 300000
ZYMEWORKS INC ZYME 2021-07-23 21:45:03 UTC -0.2539 0.3339 300000
ZYMEWORKS INC ZYME 2021-07-23 21:15:03 UTC -0.2539 0.3339 300000
ZYMEWORKS INC ZYME 2021-07-23 20:45:03 UTC -0.2511 0.3311 300000
ZYMEWORKS INC ZYME 2021-07-23 20:15:05 UTC -0.2511 0.3311 300000
ZYMEWORKS INC ZYME 2021-07-23 19:45:03 UTC -0.2511 0.3311 300000
ZYMEWORKS INC ZYME 2021-07-23 19:15:03 UTC -0.2511 0.3311 300000
ZYMEWORKS INC ZYME 2021-07-23 18:45:03 UTC -0.1963 0.2763 300000
ZYMEWORKS INC ZYME 2021-07-23 18:15:03 UTC -0.1963 0.2763 300000
ZYMEWORKS INC ZYME 2021-07-23 17:45:03 UTC -0.1963 0.2763 300000
ZYMEWORKS INC ZYME 2021-07-23 17:15:02 UTC -0.1963 0.2763 300000
ZYMEWORKS INC ZYME 2021-07-23 16:45:02 UTC -0.1906 0.2706 300000
ZYMEWORKS INC ZYME 2021-07-23 16:15:03 UTC -0.1906 0.2706 300000
ZYMEWORKS INC ZYME 2021-07-23 15:45:02 UTC -0.1906 0.2706 300000
ZYMEWORKS INC ZYME 2021-07-23 15:15:03 UTC -0.1906 0.2706 300000
ZYMEWORKS INC ZYME 2021-07-23 14:45:03 UTC -0.254 0.334 300000
ZYMEWORKS INC ZYME 2021-07-23 14:15:03 UTC -0.254 0.334 300000
ZYMEWORKS INC ZYME 2021-07-23 13:45:03 UTC -0.254 0.334 300000
ZYMEWORKS INC ZYME 2021-07-23 13:15:03 UTC -0.254 0.334 300000
ZYMEWORKS INC ZYME 2021-07-23 12:45:03 UTC -0.254 0.334 300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund ZYME -111.0 shares, $-3937.17 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund ZYME -10.0 shares, $-354.7 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund ZYME -90.0 shares, $-3192.3 2020-03-31 N-PORT

Elevate your investments